Daiichi Sankyo Co. Ltd. Ads (DSNKY) 15.4600 $DSNKY
SAVAYSA(TM) (edoxaban) Now Available in U.S. Pharmacies
PR Newswire - Mon Feb 09, 6:59AM CST
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that SAVAYSA(TM) (edoxaban), an oral, once-daily selective factor Xa-inhibitor, is now commercially available in U.S. pharmacies.
Daiichi Sankyo Announces First Patients in Large-Scale, Multi-National Phase 3 Clinical Programs for Mirogabalin
PR Newswire - Wed Feb 04, 7:00AM CST
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced enrollment of the first patients in large-scale, multi-national clinical programs evaluating the safety and efficacy of investigational mirogabalin (DS-5565), the first preferentially selective alpha-2 delta ligand. The phase 3 clinical program across Asia includes the REDUCER (An Asian, phase 3, multicenter, RandomizEd, Double-blind, placebo-controlled 14-week stUdy of DS-5565 in patients with diabetiC pEripheral neuRopathic pain followed by a 52-week open-label extension) study and the NEUCOURSE (An AsiaN, phasE 3, mUltiCenter, randomized, dOUble-blind, placebo-contRolled 14-week study of DS-5565 in patientS with postherpetic neuralgia followed by a 52-week open-label Extension) study which will evaluate investigational mirogabalin for the treatment of diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia (PHN), respectively. The phase 3 global ALDAY (A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 in Patients with Pain Associated with Fibromyalgia) clinical program is ongoing and will evaluate mirogabalin for the treatment of pain associated with fibromyalgia in three identical studies.
Dyslipidemia Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Tue Jan 27, 10:31AM CST
The report provides comprehensive information on the therapeutic development for Dyslipidemia. Dyslipidemia is an abnormal amount of cholesterol or fat in the blood. Dyslipidemia comes under consideration in many situations including diabetes, a common cause of lipidemia. Dyslipidemia is one of the major risk factors for cardiovascular disease in diabetes mellitus. Complete report is available at http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), CBAY: 11.82 (unch), NVS: 102.20 (-0.17)
Constipation Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 10:30AM CST
The report "Constipation - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Constipation. Constipation is a disorder in which a person has severe problems defecating. Constipation occurs primarily because of the lack of the bowel movement in the body. The Lack of bowel movement in the body results in hardening of stools, swollen abdomen or abdominal pain. The reasons for constipation to occur in a body are inadequate water intake, less proportion of fiber in diet, irregularities in the pattern of diet. Not maintaining proper health and inadequacy in exercise can also lead to the abnormality during defecation & would mostly end with painful symptoms. Complete Report is Available @ http://www.rnrmarketresearch.com/constipation...eport.html .
SGYP: 2.98 (unch), SHPG: 239.82 (+6.11), AZN: 69.96 (+0.20), SCMP: 15.32 (+0.04), TEVA: 56.77 (-0.58)
Atrial Fibrillation Therapeutic Pipeline Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 3:31PM CST
The report "Atrial Fibrillation - Pipeline Review, H2 2015" provides comprehensive information on the therapeutic development for atrial fibrillation. Atrial fibrillation is the most ordinary type of arrhythmia. Atrial fibrillation is an unbalanced heartbeat that increases the threat of stroke and heart disease. Generally, the risk of developing atrial fibrillation increases with age and with other risk factors such as diabetes, high blood pressure, and underlying heart disease. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. The complete report is available at http://www.rnrmarketresearch.com/atrial-fibri...eport.html .
CRME: 9.76 (-0.14), GILD: 101.90 (+1.10), AZN: 69.96 (+0.20), BMY: 60.04 (+0.56), RGDO: 1.17 (+0.02)
CAR-T Vs ErbB3 Market Opportunity Comparison
Decision Analytics - Seeking Alpha - Wed Jan 21, 12:32PM CST
CAR-T therapy, also known as "Adoptive Immunotherapy", has been the result of significant investor excitement recently. One look at the stock charts for JUNO and KITE is illustrative of this optimism. While this enthusiasm may be warranted,...
MACK: 10.22 (+0.40), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), BLCM: 20.00 (-0.81), KITE: 62.59 (+0.82), AVEO: 0.84 (-0.06), JUNO: 40.52 (+0.18), GSK: 47.94 (+1.99), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
U.S. FDA Approves Daiichi Sankyo's Once-Daily SAVAYSA(TM) (edoxaban) Tablets for Reduction of Stroke Risk in Non-Valvular Atrial Fibrillation and for the Treatment of Venous Thromboembolism
PR Newswire - Thu Jan 08, 9:03PM CST
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration (FDA) has approved SAVAYSA(TM) (edoxaban) Tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF). In ENGAGE AF-TIMI 48, SAVAYSA was non-inferior to warfarin in the overall study population for the primary efficacy endpoint of stroke or SE.1 As stated in the U.S. label, SAVAYSA should not be used in NVAF patients with creatinine clearance (CrCL) levels greater than 95 mL/min because in that population there is an increased risk of ischemic stroke compared to warfarin. Patients with CrCL less than or equal to 95 mL/min represented 77% of the patients studied. In those patients, SAVAYSA 60 mg (30 mg dose reduced) reduced the risk of stroke and SE when compared to warfarin (hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.55 to 0.84), and the rates of cardiovascular death with SAVAYSA and warfarin were 2.95% per year vs. 3.59% per year, respectively.1 The FDA also approved SAVAYSA for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant.
FDA clears Daiichi-Sankyo anticoagulant
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 6:55PM CST
PTLA: 34.96 (+3.13), PFE: 34.64 (-0.23), BMY: 60.04 (+0.56), JNJ: 99.62 (+1.18), ISIS: 63.86 (-0.43), MDCO: 29.79 (+0.91), BAX: 70.39 (+0.31), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), SCLN: 7.85 (+0.08), MSLI: 1.96 (+0.08)
Influenza A and B Infections Global Clinical Trials Review, H2, 2014 - Clinical Trial overview of the Top 10 Companies & Top 8 Institutes
M2 - Tue Jan 06, 5:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/rwt85s/influenza_a_and_b) has announced the addition of the "Influenza A and B Infections Global Clinical Trials Review, H2, 2014" report to their offering. This report provides elemental information and data relating to the clinical trials on Influenza A and B Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Influenza A and B Infections. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Daiichi Sankyo Company, Limited - GlaxoSmithKline plc - F. Hoffmann-La Roche Ltd. - Microgen Scientific Industrial Company for Immunobiological Medicines - Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Co Ltd - Crucell N.V. - Biota Pharmaceuticals, Inc. - Biota Holdings Limited (Inactive) - Beech Tree Labs, Inc. - AstraZeneca PLC Clinical Trial Overview of Top Institutes / Government - British Columbia Centre for Disease Control - West China Hospital - Nagasaki Evaluation Organization for Clinical Interventions - TJ-27 Influenza study group - The National Institute of Allergy and Infectious Diseases - Fukuoka University - University of Manitoba - University of Surrey For more information visit http://www.researchandmarkets.com/research/rw...za_a_and_b
BOTA: 2.60 (-0.06), AZN: 69.96 (+0.20), GSK: 47.94 (+1.99)
Hypertension - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv5ff/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ahn-Gook Pharmaceutical - Beijing Labsolutions Pharmaceuticals - BioLineRx - Biocon Limited - CJ CheilJedang - Chong Kun Dang Pharmaceutical - Compugen - Cytokinetics - Daewoong Pharmaceutical - Daiichi Sankyo Company - DiaMedica - Dong-A Socio - Eli Lilly and Company - GlaxoSmithKline - HanAll Biopharma - IntelGenx - LG Life Sciences - Medivir - Merck & Co - Mitsubishi Tanabe Pharma Corporation - Novartis - Palatin Technologies - Pharmazz - Sanofi - Takeda Pharmaceutical Company - Teva Pharmaceutical Industries - Toray Industries - Torrent Pharmaceuticals - Yuhan Corporation - Yungjin For more information visit http://www.researchandmarkets.com/research/hc...pertension
LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), MRK: 58.81 (-0.07), CGEN: 8.19 (+0.08), PTN: 0.72 (-0.02), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/tvqp4h/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Cardax - Connexios Life Sciences - Cubist - Daiichi Sankyo Company - Dr. Falk Pharma - Galectin Therapeutics - Galmed - Genfit - Gilead Sciences - Immuron - Intercept Pharmaceuticals - Isis Pharmaceuticals - Jenrin Discovery - Kadmon Corporation - Kissei Pharmaceutical - Kyorin Pharmaceutical - La Jolla Pharmaceutical - Mochida Pharmaceutical - NasVax - Novo Nordisk - Phenex Pharmaceuticals - ProMetic Life Sciences - Raptor Pharmaceuticals - Shire - Stelic Institute & Co - Tobira Therapeutics - Verva Pharmaceuticals - Wellstat Therapeutics - Zafgen - Zydus Cadila Healthcare For more information visit http://www.researchandmarkets.com/research/tv...nalcoholic
NVO: 43.76 (+0.61), RPTP: 9.05 (-0.40), ISIS: 63.86 (-0.43), GILD: 101.90 (+1.10), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12), TBRA: ()
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2014
M2 - Tue Dec 30, 5:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/v3x22m/bile_duct_cancer) has announced the addition of the "Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AstraZeneca - Eli Lilly and Company - Daiichi Sankyo Company - Panacea Pharmaceuticals - Exelixis - Access Pharmaceuticals - OncoTherapy Science - PCI Biotech - Provecs Medica - Agios Pharmaceuticals - Cornerstone Pharmaceuticals - NuCana BioMed Limited - Arrien Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/v3...duct_cance
LLY: 70.56 (+0.03), AGIO: 118.55 (+0.11)
Cancer Pain - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/xthht4/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - AstraZeneca - BioDelivery Sciences International - Nektar Therapeutics - Daiichi Sankyo Company - Egalet Corporation - Aphios Corporation - AcelRx Pharmaceuticals - Nippon Kayaku - Nippon Shinyaku - Orion - Pfizer - Zeria Pharmaceutical - GW Pharmaceuticals - IntelGenx - Benitec Biopharma - Kolon Life Science - Teikoku Seiyaku - BioAlliance Pharma - tesa Labtec - Colby Pharmaceutical - Grunenthal - AngioChem - WEX Pharmaceuticals - Virobay - QRxPharma - Winston Pharmaceuticals - Encore Therapeutics - Afferent Pharmaceuticals - Relevare Pharmaceuticals - Northern Light Pharmaceutical For more information visit http://www.researchandmarkets.com/research/xt...ancer_pain
BDSI: 14.92 (+0.93), ACRX: 7.29 (-0.06), EGLT: 10.60 (+0.58), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14)
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/dsgsvz/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Eli Lilly and Company - Viralytics Ltd. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Lentigen Corporation - Amorfix Life Sciences Ltd. - Piramal Enterprises Limited - Celltrion, Inc. - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - Richter Gedeon Nyrt. - Astex Pharmaceuticals, Inc. - Genmab A/S - Cyclacel Pharmaceuticals Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - Incyte Corporation - Merck KGaA - 4SC AG - Celldex Therapeutics, Inc. - Immunomedics, Inc. - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/dsgsvz/chronic
BMRN: 100.76 (+1.98), CLDX: 20.97 (+0.53), CYCC: 0.62 (-0.01), IMMU: 3.84 (unch), EBS: 28.76 (-0.12), INCY: 75.94 (+0.28), TGTX: 13.13 (-0.19), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GILD: 101.90 (+1.10), CELGZ: 3.17 (-0.04)
Ewing Sarcoma - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/l4jf65/ewing_sarcoma) has announced the addition of the "Ewing Sarcoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ewing Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ewing Sarcoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ewing Sarcoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ewing Sarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Shionogi & Co., Ltd. - Amgen Inc. - AstraZeneca PLC - Daiichi Sankyo Company, Limited - Sigma-Tau S.p.A. - Oncolytics Biotech Inc. - Merrimack Pharmaceuticals, Inc. - Pharma Mar, S.A. - EntreChem, S.L. For more information visit http://www.researchandmarkets.com/research/l4...ing_sarcom
MACK: 10.22 (+0.40), ONCY: 0.51 (+0.02), AZN: 69.96 (+0.20), AMGN: 153.48 (+0.30)
Haemophilus Influenzae Infections - Pipeline Review, H2 2013
M2 - Mon Dec 15, 3:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/f6fqrr/haemophilus) has announced the addition of the "Haemophilus Influenzae Infections - Pipeline Review, H2 2013" report to their offering. 'Haemophilus Influenzae Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Haemophilus Influenzae Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Haemophilus Influenzae Infections. Haemophilus Influenzae Infections - Pipeline Review, Half Year is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Haemophilus Influenzae Infections. - A review of the Haemophilus Influenzae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Haemophilus Influenzae Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - Dainippon Sumitomo Pharma Co., Ltd. - Wockhardt Limited - Panacea Biotec Limited For more information visit http://www.researchandmarkets.com/research/f6...aemophilus
AZN: 69.96 (+0.20), GSK: 47.94 (+1.99)
Venous Thromboembolism - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/h48x9c/venous) has announced the addition of the "Venous Thromboembolism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Venous Thromboembolism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Venous Thromboembolism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sanofi - Isis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Bayer AG - Portola Pharmaceuticals, Inc. - Green Cross Corporation - Regado Biosciences, Inc. - GlycoMimetics, Inc. - Gamma Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/h48x9c/venous
PTLA: 34.96 (+3.13), ISIS: 63.86 (-0.43), GLYC: 7.77 (+0.12), RGDO: 1.17 (+0.02)
H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014
M2 - Thu Dec 11, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/sbbrcj/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014" report to their offering. H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014" provides data on the H5N1 Infection (Avian Influenza) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on H5N1 Infection (Avian Influenza). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating H5N1 Infection (Avian Influenza). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Novartis AG - GlaxoSmithKline plc - Baxter International Inc. - Mitsubishi Tanabe Pharma Corporation - AstraZeneca PLC - Microgen Scientific Industrial Company for Immunobiological Medicines - Green Cross Holdings Corporation - Generex Biotechnology Corporation - Daiichi Sankyo Company, Limited - CSL Limited Clinical Trial Overview of Top Institutes / Government - The National Institute of Allergy and Infectious Diseases - Mahidol University - National Hospital Organization Mie National Hospital - The Chemo-Sero-Therapeutic Research Institute - Clinical Research Center, National Hospital Organization - Queen Mary Hospital - Tohoku University Graduate School of Medicine, Department Of Surgery - Fraunhofer Center for Molecular Biotechnology - South East Asia Infectious Disease Clinical Research Network For more information visit http://www.researchandmarkets.com/research/sb..._infection
BAX: 70.39 (+0.31), AZN: 69.96 (+0.20), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
Community-Acquired Infections Global Clinical Trials Review, H2, 2014
M2 - Thu Dec 11, 6:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/hxr44r/communityacquired) has announced the addition of the "Community-Acquired Infections Global Clinical Trials Review, H2, 2014" report to their offering. Community-Acquired Infections Global Clinical Trials Review, H2, 2014" provides data on the Community-Acquired Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Community-Acquired Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Community-Acquired Infections. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - GlaxoSmithKline plc - Pfizer Inc. - Panacea Biotec Limited - Daiichi Sankyo Company, Limited - Tetraphase Pharmaceuticals Inc. - TaiGen Biopharmaceuticals Holdings Limited - Janssen Research & Development, LLC - Dong Wha Pharma Co., Ltd. - Cubist Pharmaceuticals, Inc. - Belpharma S.A. Clinical Trial Overview of Top Institutes / Government - Hanyang University Medical Center - Ewha Womans University - Kyungpook National University - Katholieke Universiteit Leuven - Rennes University Hospital - University of Milan For more information visit http://www.researchandmarkets.com/research/hx...tyacquired About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
TTPH: 35.18 (-0.73), CBSTZ: 0.06 (unch), PFE: 34.64 (-0.23), GSK: 47.94 (+1.99)
Duchenne Muscular Dystrophy - Pipeline Review, H2 2014
M2 - Thu Dec 11, 4:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/rxfljh/duchenne_muscular) has announced the addition of the "Duchenne Muscular Dystrophy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Duchenne Muscular Dystrophy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy pipeline depth and focus of indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sanofi - Eli Lilly and Company - Daiichi Sankyo Company - Nippon Shinyaku - Zambon - Sarepta - NicOx - Lexicon - Galapagos - Summit - Santhera - Shenzhen Beike Biotechnology - Italfarmaco - Acceleron - Prosensa - Catabasis - Nobelpharma - PTC - Reata - Fate - N-Gene - Asklepios - Genethon - miRagen - Prosensa - Tarix - EryDel - Myomics - Prothelia - ReveraGen BioPharma - Retrophin For more information visit http://www.researchandmarkets.com/research/rx...e_muscular
LLY: 70.56 (+0.03)
SAVAYSA(TM) (edoxaban) Now Available in U.S. Pharmacies
PR Newswire - Mon Feb 09, 6:59AM CST
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that SAVAYSA(TM) (edoxaban), an oral, once-daily selective factor Xa-inhibitor, is now commercially available in U.S. pharmacies.
Daiichi Sankyo Announces First Patients in Large-Scale, Multi-National Phase 3 Clinical Programs for Mirogabalin
PR Newswire - Wed Feb 04, 7:00AM CST
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced enrollment of the first patients in large-scale, multi-national clinical programs evaluating the safety and efficacy of investigational mirogabalin (DS-5565), the first preferentially selective alpha-2 delta ligand. The phase 3 clinical program across Asia includes the REDUCER (An Asian, phase 3, multicenter, RandomizEd, Double-blind, placebo-controlled 14-week stUdy of DS-5565 in patients with diabetiC pEripheral neuRopathic pain followed by a 52-week open-label extension) study and the NEUCOURSE (An AsiaN, phasE 3, mUltiCenter, randomized, dOUble-blind, placebo-contRolled 14-week study of DS-5565 in patientS with postherpetic neuralgia followed by a 52-week open-label Extension) study which will evaluate investigational mirogabalin for the treatment of diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia (PHN), respectively. The phase 3 global ALDAY (A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 in Patients with Pain Associated with Fibromyalgia) clinical program is ongoing and will evaluate mirogabalin for the treatment of pain associated with fibromyalgia in three identical studies.
Dyslipidemia Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Tue Jan 27, 10:31AM CST
The report provides comprehensive information on the therapeutic development for Dyslipidemia. Dyslipidemia is an abnormal amount of cholesterol or fat in the blood. Dyslipidemia comes under consideration in many situations including diabetes, a common cause of lipidemia. Dyslipidemia is one of the major risk factors for cardiovascular disease in diabetes mellitus. Complete report is available at http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), CBAY: 11.82 (unch), NVS: 102.20 (-0.17)
Constipation Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 10:30AM CST
The report "Constipation - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Constipation. Constipation is a disorder in which a person has severe problems defecating. Constipation occurs primarily because of the lack of the bowel movement in the body. The Lack of bowel movement in the body results in hardening of stools, swollen abdomen or abdominal pain. The reasons for constipation to occur in a body are inadequate water intake, less proportion of fiber in diet, irregularities in the pattern of diet. Not maintaining proper health and inadequacy in exercise can also lead to the abnormality during defecation & would mostly end with painful symptoms. Complete Report is Available @ http://www.rnrmarketresearch.com/constipation...eport.html .
SGYP: 2.98 (unch), SHPG: 239.82 (+6.11), AZN: 69.96 (+0.20), SCMP: 15.32 (+0.04), TEVA: 56.77 (-0.58)
Atrial Fibrillation Therapeutic Pipeline Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 3:31PM CST
The report "Atrial Fibrillation - Pipeline Review, H2 2015" provides comprehensive information on the therapeutic development for atrial fibrillation. Atrial fibrillation is the most ordinary type of arrhythmia. Atrial fibrillation is an unbalanced heartbeat that increases the threat of stroke and heart disease. Generally, the risk of developing atrial fibrillation increases with age and with other risk factors such as diabetes, high blood pressure, and underlying heart disease. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. The complete report is available at http://www.rnrmarketresearch.com/atrial-fibri...eport.html .
CRME: 9.76 (-0.14), GILD: 101.90 (+1.10), AZN: 69.96 (+0.20), BMY: 60.04 (+0.56), RGDO: 1.17 (+0.02)
CAR-T Vs ErbB3 Market Opportunity Comparison
Decision Analytics - Seeking Alpha - Wed Jan 21, 12:32PM CST
CAR-T therapy, also known as "Adoptive Immunotherapy", has been the result of significant investor excitement recently. One look at the stock charts for JUNO and KITE is illustrative of this optimism. While this enthusiasm may be warranted,...
MACK: 10.22 (+0.40), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), BLCM: 20.00 (-0.81), KITE: 62.59 (+0.82), AVEO: 0.84 (-0.06), JUNO: 40.52 (+0.18), GSK: 47.94 (+1.99), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
U.S. FDA Approves Daiichi Sankyo's Once-Daily SAVAYSA(TM) (edoxaban) Tablets for Reduction of Stroke Risk in Non-Valvular Atrial Fibrillation and for the Treatment of Venous Thromboembolism
PR Newswire - Thu Jan 08, 9:03PM CST
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration (FDA) has approved SAVAYSA(TM) (edoxaban) Tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF). In ENGAGE AF-TIMI 48, SAVAYSA was non-inferior to warfarin in the overall study population for the primary efficacy endpoint of stroke or SE.1 As stated in the U.S. label, SAVAYSA should not be used in NVAF patients with creatinine clearance (CrCL) levels greater than 95 mL/min because in that population there is an increased risk of ischemic stroke compared to warfarin. Patients with CrCL less than or equal to 95 mL/min represented 77% of the patients studied. In those patients, SAVAYSA 60 mg (30 mg dose reduced) reduced the risk of stroke and SE when compared to warfarin (hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.55 to 0.84), and the rates of cardiovascular death with SAVAYSA and warfarin were 2.95% per year vs. 3.59% per year, respectively.1 The FDA also approved SAVAYSA for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant.
FDA clears Daiichi-Sankyo anticoagulant
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 6:55PM CST
PTLA: 34.96 (+3.13), PFE: 34.64 (-0.23), BMY: 60.04 (+0.56), JNJ: 99.62 (+1.18), ISIS: 63.86 (-0.43), MDCO: 29.79 (+0.91), BAX: 70.39 (+0.31), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), SCLN: 7.85 (+0.08), MSLI: 1.96 (+0.08)
Influenza A and B Infections Global Clinical Trials Review, H2, 2014 - Clinical Trial overview of the Top 10 Companies & Top 8 Institutes
M2 - Tue Jan 06, 5:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/rwt85s/influenza_a_and_b) has announced the addition of the "Influenza A and B Infections Global Clinical Trials Review, H2, 2014" report to their offering. This report provides elemental information and data relating to the clinical trials on Influenza A and B Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Influenza A and B Infections. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Daiichi Sankyo Company, Limited - GlaxoSmithKline plc - F. Hoffmann-La Roche Ltd. - Microgen Scientific Industrial Company for Immunobiological Medicines - Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Co Ltd - Crucell N.V. - Biota Pharmaceuticals, Inc. - Biota Holdings Limited (Inactive) - Beech Tree Labs, Inc. - AstraZeneca PLC Clinical Trial Overview of Top Institutes / Government - British Columbia Centre for Disease Control - West China Hospital - Nagasaki Evaluation Organization for Clinical Interventions - TJ-27 Influenza study group - The National Institute of Allergy and Infectious Diseases - Fukuoka University - University of Manitoba - University of Surrey For more information visit http://www.researchandmarkets.com/research/rw...za_a_and_b
BOTA: 2.60 (-0.06), AZN: 69.96 (+0.20), GSK: 47.94 (+1.99)
Hypertension - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv5ff/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ahn-Gook Pharmaceutical - Beijing Labsolutions Pharmaceuticals - BioLineRx - Biocon Limited - CJ CheilJedang - Chong Kun Dang Pharmaceutical - Compugen - Cytokinetics - Daewoong Pharmaceutical - Daiichi Sankyo Company - DiaMedica - Dong-A Socio - Eli Lilly and Company - GlaxoSmithKline - HanAll Biopharma - IntelGenx - LG Life Sciences - Medivir - Merck & Co - Mitsubishi Tanabe Pharma Corporation - Novartis - Palatin Technologies - Pharmazz - Sanofi - Takeda Pharmaceutical Company - Teva Pharmaceutical Industries - Toray Industries - Torrent Pharmaceuticals - Yuhan Corporation - Yungjin For more information visit http://www.researchandmarkets.com/research/hc...pertension
LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), MRK: 58.81 (-0.07), CGEN: 8.19 (+0.08), PTN: 0.72 (-0.02), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/tvqp4h/nonalcoholic) has announced the addition of the "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Cardax - Connexios Life Sciences - Cubist - Daiichi Sankyo Company - Dr. Falk Pharma - Galectin Therapeutics - Galmed - Genfit - Gilead Sciences - Immuron - Intercept Pharmaceuticals - Isis Pharmaceuticals - Jenrin Discovery - Kadmon Corporation - Kissei Pharmaceutical - Kyorin Pharmaceutical - La Jolla Pharmaceutical - Mochida Pharmaceutical - NasVax - Novo Nordisk - Phenex Pharmaceuticals - ProMetic Life Sciences - Raptor Pharmaceuticals - Shire - Stelic Institute & Co - Tobira Therapeutics - Verva Pharmaceuticals - Wellstat Therapeutics - Zafgen - Zydus Cadila Healthcare For more information visit http://www.researchandmarkets.com/research/tv...nalcoholic
NVO: 43.76 (+0.61), RPTP: 9.05 (-0.40), ISIS: 63.86 (-0.43), GILD: 101.90 (+1.10), GALT: 3.84 (+0.16), ICPT: 209.12 (+7.12), TBRA: ()
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2014
M2 - Tue Dec 30, 5:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/v3x22m/bile_duct_cancer) has announced the addition of the "Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AstraZeneca - Eli Lilly and Company - Daiichi Sankyo Company - Panacea Pharmaceuticals - Exelixis - Access Pharmaceuticals - OncoTherapy Science - PCI Biotech - Provecs Medica - Agios Pharmaceuticals - Cornerstone Pharmaceuticals - NuCana BioMed Limited - Arrien Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/v3...duct_cance
LLY: 70.56 (+0.03), AGIO: 118.55 (+0.11)
Cancer Pain - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/xthht4/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - AstraZeneca - BioDelivery Sciences International - Nektar Therapeutics - Daiichi Sankyo Company - Egalet Corporation - Aphios Corporation - AcelRx Pharmaceuticals - Nippon Kayaku - Nippon Shinyaku - Orion - Pfizer - Zeria Pharmaceutical - GW Pharmaceuticals - IntelGenx - Benitec Biopharma - Kolon Life Science - Teikoku Seiyaku - BioAlliance Pharma - tesa Labtec - Colby Pharmaceutical - Grunenthal - AngioChem - WEX Pharmaceuticals - Virobay - QRxPharma - Winston Pharmaceuticals - Encore Therapeutics - Afferent Pharmaceuticals - Relevare Pharmaceuticals - Northern Light Pharmaceutical For more information visit http://www.researchandmarkets.com/research/xt...ancer_pain
BDSI: 14.92 (+0.93), ACRX: 7.29 (-0.06), EGLT: 10.60 (+0.58), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14)
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/dsgsvz/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Eli Lilly and Company - Viralytics Ltd. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Lentigen Corporation - Amorfix Life Sciences Ltd. - Piramal Enterprises Limited - Celltrion, Inc. - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - Richter Gedeon Nyrt. - Astex Pharmaceuticals, Inc. - Genmab A/S - Cyclacel Pharmaceuticals Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - Incyte Corporation - Merck KGaA - 4SC AG - Celldex Therapeutics, Inc. - Immunomedics, Inc. - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/dsgsvz/chronic
BMRN: 100.76 (+1.98), CLDX: 20.97 (+0.53), CYCC: 0.62 (-0.01), IMMU: 3.84 (unch), EBS: 28.76 (-0.12), INCY: 75.94 (+0.28), TGTX: 13.13 (-0.19), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GILD: 101.90 (+1.10), CELGZ: 3.17 (-0.04)
Ewing Sarcoma - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/l4jf65/ewing_sarcoma) has announced the addition of the "Ewing Sarcoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ewing Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ewing Sarcoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ewing Sarcoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ewing Sarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Shionogi & Co., Ltd. - Amgen Inc. - AstraZeneca PLC - Daiichi Sankyo Company, Limited - Sigma-Tau S.p.A. - Oncolytics Biotech Inc. - Merrimack Pharmaceuticals, Inc. - Pharma Mar, S.A. - EntreChem, S.L. For more information visit http://www.researchandmarkets.com/research/l4...ing_sarcom
MACK: 10.22 (+0.40), ONCY: 0.51 (+0.02), AZN: 69.96 (+0.20), AMGN: 153.48 (+0.30)
Haemophilus Influenzae Infections - Pipeline Review, H2 2013
M2 - Mon Dec 15, 3:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/f6fqrr/haemophilus) has announced the addition of the "Haemophilus Influenzae Infections - Pipeline Review, H2 2013" report to their offering. 'Haemophilus Influenzae Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Haemophilus Influenzae Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Haemophilus Influenzae Infections. Haemophilus Influenzae Infections - Pipeline Review, Half Year is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Haemophilus Influenzae Infections. - A review of the Haemophilus Influenzae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Haemophilus Influenzae Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - Dainippon Sumitomo Pharma Co., Ltd. - Wockhardt Limited - Panacea Biotec Limited For more information visit http://www.researchandmarkets.com/research/f6...aemophilus
AZN: 69.96 (+0.20), GSK: 47.94 (+1.99)
Venous Thromboembolism - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/h48x9c/venous) has announced the addition of the "Venous Thromboembolism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Venous Thromboembolism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Venous Thromboembolism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sanofi - Isis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Bayer AG - Portola Pharmaceuticals, Inc. - Green Cross Corporation - Regado Biosciences, Inc. - GlycoMimetics, Inc. - Gamma Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/h48x9c/venous
PTLA: 34.96 (+3.13), ISIS: 63.86 (-0.43), GLYC: 7.77 (+0.12), RGDO: 1.17 (+0.02)
H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014
M2 - Thu Dec 11, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/sbbrcj/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014" report to their offering. H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014" provides data on the H5N1 Infection (Avian Influenza) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on H5N1 Infection (Avian Influenza). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating H5N1 Infection (Avian Influenza). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Novartis AG - GlaxoSmithKline plc - Baxter International Inc. - Mitsubishi Tanabe Pharma Corporation - AstraZeneca PLC - Microgen Scientific Industrial Company for Immunobiological Medicines - Green Cross Holdings Corporation - Generex Biotechnology Corporation - Daiichi Sankyo Company, Limited - CSL Limited Clinical Trial Overview of Top Institutes / Government - The National Institute of Allergy and Infectious Diseases - Mahidol University - National Hospital Organization Mie National Hospital - The Chemo-Sero-Therapeutic Research Institute - Clinical Research Center, National Hospital Organization - Queen Mary Hospital - Tohoku University Graduate School of Medicine, Department Of Surgery - Fraunhofer Center for Molecular Biotechnology - South East Asia Infectious Disease Clinical Research Network For more information visit http://www.researchandmarkets.com/research/sb..._infection
BAX: 70.39 (+0.31), AZN: 69.96 (+0.20), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
Community-Acquired Infections Global Clinical Trials Review, H2, 2014
M2 - Thu Dec 11, 6:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/hxr44r/communityacquired) has announced the addition of the "Community-Acquired Infections Global Clinical Trials Review, H2, 2014" report to their offering. Community-Acquired Infections Global Clinical Trials Review, H2, 2014" provides data on the Community-Acquired Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Community-Acquired Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Community-Acquired Infections. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - GlaxoSmithKline plc - Pfizer Inc. - Panacea Biotec Limited - Daiichi Sankyo Company, Limited - Tetraphase Pharmaceuticals Inc. - TaiGen Biopharmaceuticals Holdings Limited - Janssen Research & Development, LLC - Dong Wha Pharma Co., Ltd. - Cubist Pharmaceuticals, Inc. - Belpharma S.A. Clinical Trial Overview of Top Institutes / Government - Hanyang University Medical Center - Ewha Womans University - Kyungpook National University - Katholieke Universiteit Leuven - Rennes University Hospital - University of Milan For more information visit http://www.researchandmarkets.com/research/hx...tyacquired About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
TTPH: 35.18 (-0.73), CBSTZ: 0.06 (unch), PFE: 34.64 (-0.23), GSK: 47.94 (+1.99)
Duchenne Muscular Dystrophy - Pipeline Review, H2 2014
M2 - Thu Dec 11, 4:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/rxfljh/duchenne_muscular) has announced the addition of the "Duchenne Muscular Dystrophy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Duchenne Muscular Dystrophy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy pipeline depth and focus of indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sanofi - Eli Lilly and Company - Daiichi Sankyo Company - Nippon Shinyaku - Zambon - Sarepta - NicOx - Lexicon - Galapagos - Summit - Santhera - Shenzhen Beike Biotechnology - Italfarmaco - Acceleron - Prosensa - Catabasis - Nobelpharma - PTC - Reata - Fate - N-Gene - Asklepios - Genethon - miRagen - Prosensa - Tarix - EryDel - Myomics - Prothelia - ReveraGen BioPharma - Retrophin For more information visit http://www.researchandmarkets.com/research/rx...e_muscular
LLY: 70.56 (+0.03)
